Enliven Therapeutics (Nasdaq: ELVN) founder files Form 144 to sell 100,000

Rhea-AI Filing Summary

Enliven Therapeutics filed a Form 144 to sell 100,000 common shares. The notice lists these as founder shares with Jefferies LLC as broker and an intended sale on 03/24/2026 on Nasdaq.

The filing also discloses a prior sale of 48,300 shares by Anish Patel on 01/09/2026 for $1,351,761.47. The filing presents the proposed sale quantity and a recent disposition by an insider.

Insights

Insider Transactions Analyst

Founder notice lists a proposed resale of 100,000 shares and a recent 48,300-share sale.

The filing identifies 100,000 founder shares proposed for sale through Jefferies LLC with Nasdaq listed as the market and an intended date of 03/24/2026. This is a Rule 144 notice describing a planned resale, not a company capital raise.

Prior activity includes a sale of 48,300 shares by Anish Patel on 01/09/2026 for $1,351,761.47. Follow-up filings will show actual execution and any remaining holdings; timing and cash‑flow treatment are as stated on subsequent transaction reports.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Jefferies LLC 520 Madison Ave 4th Fl New York NY 10022	100000	3081000.00	59000000	03/24/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/01/2019	Founder shares	Enliven Therapeutics			100000	09/01/2019	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Anish Patel 6200 Lookout Rd 1st Fl Boulder CO 80301	Enliven Therapeutics	01/09/2026	48300	1351761.47

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Enliven Therapeutics' Form 144 disclose (ELVN)?

It discloses a proposed sale of 100,000 common founder shares via Jefferies LLC with an intended market of Nasdaq on 03/24/2026. It also notes a prior insider sale of 48,300 shares on 01/09/2026.

Who is listed as the selling insider in the filing for ELVN?

The filing shows Anish Patel as a discloser of prior sales and lists founder shares as the class involved. The notice names Jefferies LLC as the broker for the proposed sale scheduled on 03/24/2026.

How many shares were sold recently by insiders of Enliven (ELVN)?

The filing reports a sale of 48,300 shares on 01/09/2026 attributed to Anish Patel, generating $1,351,761.47. The document separates this past sale from the newly proposed 100,000-share notice.

Does the Form 144 show when the 100,000 shares will be sold?

Yes. The notice lists an intended sale date of 03/24/2026 and identifies Nasdaq as the market. The filing states the proposed quantity and broker but does not report execution until a subsequent transaction filing if sales occur.

Which broker is handling the proposed resale in the ELVN Form 144?

The broker named in the notice is Jefferies LLC at 520 Madison Ave, New York. The filing pairs Jefferies with the proposed sale of 100,000 founder shares on 03/24/2026 on Nasdaq.